LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
LEXICON PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.55+0.03 (+1.97%)
Close on Oct 19, 2026
- Market cap
- $678.36M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
99.4%+7.5 pts over 5 years
Operating margin
-98.2%+101.0 pts over 5 years
Net margin
-101.1%+143.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +60.2% | +610.3% | +15.7% | -9.1% | |
| Gross profit | +62.6% | +608.9% | +17.6% | -9.2% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -58.0% | -42.8% | -39.7% | |
| Return on assets | -23.3% | -18.8% | -20.8% | |
| Current ratio | 2.17 | 3.37 | 4.88 | |
| Debt to equity | 0.61 | 0.07 | 0.50 | |
| Net debt to EBITDA | -0.44× | 2.55× | -0.41× | |
| Interest coverage | -19.4× | -3.3× | – | |
| Inventory turnover | – | 0.9× | 1.1× | |
| Capex to revenue | 0.3% | 0.4% | 0.0% | |
| Diluted shares | 104M | 111M | 363M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Lexicon Pharmaceuticals generated $584.40M from operations and spent $10.14M on capital expenditure, dividends and share buybacks. 40% of that went back into the business.
Generated
$584.40M
Used
$10.14M
Capital expenditure$4.05M40%Dividends$00%Share buybacks$6.09M60%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-101.1%
×Asset turnover0.21×
×Equity multiplier1.91×
=Return on equity, FY2025-39.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -101.1% | 0.21× | 1.91× | -39.7% |
| FY2024 | -644.8% | 0.12× | 2.21× | -167.7% |
| FY2023 | -14710.9% | 0.01× | 2.02× | -168.5% |
| FY2022 | -73341.0% | 0.00× | 1.44× | -88.4% |
| FY2021 | -29449.0% | 0.00× | 1.26× | -65.0% |
| FY2020 | -244.1% | 0.08× | 2.27× | -42.8% |
| FY2019 | 40.4% | 0.92× | 7.74× | 287.0% |
| FY2018 | -190.7% | 0.18× | 17.22× | -576.0% |
| FY2017 | -134.1% | 0.20× | 3.87× | -104.3% |
| FY2016 | -165.8% | 0.14× | 2.49× | -58.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$50.34M
- Cash generatingOperating cash flow above zero-$67.85M
- Return on assets improvedROA up on the prior year-87.3% → -16.9%
- Earnings backed by cashOperating cash flow above net income-$67.85M vs -$50.34M
- Less leverageLong-term debt to assets fell33.6% → 26.7%
- Better liquidityCurrent ratio rose5.44 → 4.88
- No dilutionShare count did not rise320M → 363M
- Gross margin improvedGross margin up on the prior year98.02% → 99.45%
- More efficientAsset turnover rose0.14 → 0.17